Cargando…

Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature

PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshirfar, Majid, Thomson, Andrew C, West, William B, Hall, MacGregor N, McCabe, Shannon E, Thomson, Robert J, Ronquillo, Yasmyne C, Hoopes, Phillip C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607143/
https://www.ncbi.nlm.nih.gov/pubmed/33154614
http://dx.doi.org/10.2147/OPTH.S276899
_version_ 1783604585976299520
author Moshirfar, Majid
Thomson, Andrew C
West, William B
Hall, MacGregor N
McCabe, Shannon E
Thomson, Robert J
Ronquillo, Yasmyne C
Hoopes, Phillip C
author_facet Moshirfar, Majid
Thomson, Andrew C
West, William B
Hall, MacGregor N
McCabe, Shannon E
Thomson, Robert J
Ronquillo, Yasmyne C
Hoopes, Phillip C
author_sort Moshirfar, Majid
collection PubMed
description PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean preoperative sphere of −5.11 ± 1.31 diopters (D) and cylinder of −1.12 ± 0.60 D underwent SMILE. Visual acuity, refractive, and vector analysis outcomes as well as subjective measures were reported at three and twelve months postoperatively and compared with FDA results and the published literature between 2014 and 2020 involving treatment of patients with mean cylinders of >−0.50 to ≤−3.00 D. RESULTS: At three and twelve months, 43 and 32 eyes were evaluated, respectively. At twelve months, mean cylinder power was reduced to −0.38 ± 0.38 D with 78.1% achieving ≤±0.50 D. Uncorrected distance visual acuity (UDVA) ≥20/20 was achieved in 77.4% of eyes by twelve months with 100% achieving ≥20/30 UDVA. No loss of corrected distance visual acuity was observed in eyes seen at twelve months. Correction index (CI) at twelve months was 0.90 indicating overall undercorrection of 10%. Twelve-month CI was 0.96, 0.90, and 0.83 in eyes with preoperative cylinders of <−1.00 D, ≥−1.00 to <−2.00 D, and ≥−2.00 D, respectively. Mean angle of error was −1.58 ± 11.61° ranging from −24.22° to 37.75°. CONCLUSION: We found SMILE to be an effective and safe means of achieving spectacle independence and improving visual acuity in patients with myopic astigmatism. SMILE has the potential for improved clinical outcomes with better nomogram guidance and advancements in technique. However, surgeons must be aware of the potential for undercorrection in with-the-rule astigmatism and at higher preoperative cylinders and as well as the potential for overcorrection in against-the-rule and lower preoperative cylinder astigmatism.
format Online
Article
Text
id pubmed-7607143
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76071432020-11-04 Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature Moshirfar, Majid Thomson, Andrew C West, William B Hall, MacGregor N McCabe, Shannon E Thomson, Robert J Ronquillo, Yasmyne C Hoopes, Phillip C Clin Ophthalmol Original Research PURPOSE: To assess a single site’s initial experience with SMILE for the treatment of myopic astigmatism and compare outcomes and vector analysis results with the US Food and Drug Administration (FDA) results and published literature. PATIENTS AND METHODS: Forty-eight eyes (29 patients) with mean preoperative sphere of −5.11 ± 1.31 diopters (D) and cylinder of −1.12 ± 0.60 D underwent SMILE. Visual acuity, refractive, and vector analysis outcomes as well as subjective measures were reported at three and twelve months postoperatively and compared with FDA results and the published literature between 2014 and 2020 involving treatment of patients with mean cylinders of >−0.50 to ≤−3.00 D. RESULTS: At three and twelve months, 43 and 32 eyes were evaluated, respectively. At twelve months, mean cylinder power was reduced to −0.38 ± 0.38 D with 78.1% achieving ≤±0.50 D. Uncorrected distance visual acuity (UDVA) ≥20/20 was achieved in 77.4% of eyes by twelve months with 100% achieving ≥20/30 UDVA. No loss of corrected distance visual acuity was observed in eyes seen at twelve months. Correction index (CI) at twelve months was 0.90 indicating overall undercorrection of 10%. Twelve-month CI was 0.96, 0.90, and 0.83 in eyes with preoperative cylinders of <−1.00 D, ≥−1.00 to <−2.00 D, and ≥−2.00 D, respectively. Mean angle of error was −1.58 ± 11.61° ranging from −24.22° to 37.75°. CONCLUSION: We found SMILE to be an effective and safe means of achieving spectacle independence and improving visual acuity in patients with myopic astigmatism. SMILE has the potential for improved clinical outcomes with better nomogram guidance and advancements in technique. However, surgeons must be aware of the potential for undercorrection in with-the-rule astigmatism and at higher preoperative cylinders and as well as the potential for overcorrection in against-the-rule and lower preoperative cylinder astigmatism. Dove 2020-10-29 /pmc/articles/PMC7607143/ /pubmed/33154614 http://dx.doi.org/10.2147/OPTH.S276899 Text en © 2020 Moshirfar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Moshirfar, Majid
Thomson, Andrew C
West, William B
Hall, MacGregor N
McCabe, Shannon E
Thomson, Robert J
Ronquillo, Yasmyne C
Hoopes, Phillip C
Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title_full Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title_fullStr Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title_full_unstemmed Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title_short Initial Single-Site Experience Using SMILE for the Treatment of Astigmatism in Myopic Eyes and Comparison of Astigmatic Outcomes with Existing Literature
title_sort initial single-site experience using smile for the treatment of astigmatism in myopic eyes and comparison of astigmatic outcomes with existing literature
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607143/
https://www.ncbi.nlm.nih.gov/pubmed/33154614
http://dx.doi.org/10.2147/OPTH.S276899
work_keys_str_mv AT moshirfarmajid initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT thomsonandrewc initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT westwilliamb initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT hallmacgregorn initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT mccabeshannone initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT thomsonrobertj initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT ronquilloyasmynec initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature
AT hoopesphillipc initialsinglesiteexperienceusingsmileforthetreatmentofastigmatisminmyopiceyesandcomparisonofastigmaticoutcomeswithexistingliterature